📰 Recursion Pharmaceuticals Competitors News
Recursion Pharmaceuticals Competitors News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Recursion Pharmaceuticals Competitors. Real-time updates on events, politics, business and more.
April 24, 2022
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Rating) is one of 254 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its competitors? We will compare Recursion Pharmaceuticals to related businesses based on the strength of its dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation. Insider & Institutional Ownership […]
April 23, 2022
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Rating) is one of 254 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare Recursion Pharmaceuticals to related companies based on the strength of its dividends, institutional ownership, valuation, profitability, risk, analyst recommendations and earnings. Valuation and Earnings This […]
April 21, 2022
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Rating) is one of 254 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its rivals? We will compare Recursion Pharmaceuticals to related businesses based on the strength of its analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings. Valuation and […]
April 15, 2022
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Rating) is one of 254 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare Recursion Pharmaceuticals to similar companies based on the strength of its risk, institutional ownership, dividends, valuation, analyst recommendations, profitability and earnings. Valuation & Earnings This […]